Cited 21 times in
Pathologic and Oncologic Outcomes in Locally Advanced Gastric Cancer with Neoadjuvant Chemotherapy or Chemoradiotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김충배 | - |
dc.contributor.author | 김형일 | - |
dc.contributor.author | 노성훈 | - |
dc.contributor.author | 안지영 | - |
dc.contributor.author | 정재호 | - |
dc.contributor.author | 형우진 | - |
dc.date.accessioned | 2014-12-18T08:47:41Z | - |
dc.date.available | 2014-12-18T08:47:41Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/86964 | - |
dc.description.abstract | PURPOSE: Although neoadjuvant therapy has been accepted as a treatment option in locally-advanced gastric cancer, its prognostic value has been difficult to evaluate. MATERIALS AND METHODS: Seventy-four gastric cancer patients who underwent gastrectomy after neoadjuvant treatment were divided into two groups according to the pathologic response: favorable (ypT0) and others (ypT1-4). The clinicopathologic characteristics, predictive factors for pathologic response, and oncologic outcome were evaluated. RESULTS: Eleven patients (14.8%) demonstrated ypT0 and the remaining 63 patients (85.2%) were ypT1-4. Chemoradiotherapy (CCRTx) rather than chemotherapy (CTx) was the only predictive factor for a favorable pathologic response. Chemotherapeutic factors and tumor marker levels did not predict pathologic response. The 1-, 2-, and 3-year disease-free survivals were 83.4%, 70%, and 52.2%. The 1-, 3-, 5-year overall survivals were 88.5%, 67.5%, and 51.2%, respectively. Although a complete pathologic response (ypT0N0M0) was achieved in 7 patients, 28.6% of them demonstrated recurrence of the tumor within 6 months after curative surgery. CONCLUSION: CCRTx rather than CTx appears to be more effective for achieving good pathologic response. Although favorable pathologic response has been achieved after neoadjuvant treatment, the survival benefit remains controversial. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Biomarkers, Tumor | - |
dc.subject.MESH | Chemoradiotherapy/methods* | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Gastrectomy | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoadjuvant Therapy | - |
dc.subject.MESH | Neoplasm Recurrence, Local/pathology | - |
dc.subject.MESH | Stomach Neoplasms/drug therapy* | - |
dc.subject.MESH | Stomach Neoplasms/mortality | - |
dc.subject.MESH | Stomach Neoplasms/pathology | - |
dc.subject.MESH | Stomach Neoplasms/radiotherapy* | - |
dc.subject.MESH | Stomach Neoplasms/surgery | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Pathologic and Oncologic Outcomes in Locally Advanced Gastric Cancer with Neoadjuvant Chemotherapy or Chemoradiotherapy | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학) | - |
dc.contributor.googleauthor | Ji Yeong An | - |
dc.contributor.googleauthor | Hyoung-Il Kim | - |
dc.contributor.googleauthor | Jae-Ho Cheong | - |
dc.contributor.googleauthor | Woo Jin Hyung | - |
dc.contributor.googleauthor | Choong Bae Kim | - |
dc.contributor.googleauthor | Sung Hoon Noh | - |
dc.identifier.doi | 10.3349/ymj.2013.54.4.888 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01063 | - |
dc.contributor.localId | A01154 | - |
dc.contributor.localId | A01281 | - |
dc.contributor.localId | A03717 | - |
dc.contributor.localId | A04382 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 23709422 | - |
dc.subject.keyword | Gastric cancer | - |
dc.subject.keyword | gastrectomy | - |
dc.subject.keyword | neoadjuvant chemoradiotherapy | - |
dc.subject.keyword | neoadjuvant chemotherapy | - |
dc.subject.keyword | pathologic response | - |
dc.subject.keyword | prognosis | - |
dc.contributor.alternativeName | Kim, Choong Bai | - |
dc.contributor.alternativeName | Kim, Hyoung Il | - |
dc.contributor.alternativeName | Noh, Sung Hoon | - |
dc.contributor.alternativeName | An, Ji Yeong | - |
dc.contributor.alternativeName | Cheong, Jae Ho | - |
dc.contributor.alternativeName | Hyung, Woo Jin | - |
dc.contributor.affiliatedAuthor | Kim, Choong Bai | - |
dc.contributor.affiliatedAuthor | Kim, Hyoung Il | - |
dc.contributor.affiliatedAuthor | Noh, Sung Hoon | - |
dc.contributor.affiliatedAuthor | Cheong, Jae Ho | - |
dc.contributor.affiliatedAuthor | Hyung, Woo Jin | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 54 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 888 | - |
dc.citation.endPage | 894 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.54(4) : 888-894, 2013 | - |
dc.identifier.rimsid | 32064 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.